secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vyome Holdings, Inc (HIND)
CIK:        0001427570
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001558370-24-012263
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ReShape Lifesciences enters merger with Vyome Therapeutics, sells assets to Biorad for $5.16M
--------------------------------------------------------------------------------

- Q2 revenue $2.0M (-12.8% YoY); six-month revenue $3.9M (-13.9% YoY); gross margin improved to 57.7%.
- Operating expenses down 45.4% in first half; sales & marketing fell 69.2% in Q2 to $0.7M.
- Cash and restricted cash $1.2M as of June 30, with net working capital $2.9M.
- Merger with Vyome: all-stock deal; ReShape stockholders to own ~11.1% of combined company.
- Asset sale to Biorad Medisys for $5.16M cash; assets include Lap-Band and Obalon systems.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427570/000155837024012263/0001558370-24-012263-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427570/000155837024012263/rsls-20240814x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-012263

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer